Tarsus Pharma (TARS): Revenue Growth QoQ

Corporate company logo of Tarsus Corp (TARS)

The future of Tarsus Pharmaceuticals (TARS) depends on the recognition of Xdemvy by US insurance companies. This GURU.Markets terminal chart, illustrating the history of quarterly revenue changes, confirms the success of a strategy to capture an empty niche via an IT platform for ophthalmologists. Simultaneously, the business is expanding into the rosacea and Lyme disease markets. The value of 63.90 sets the current metric, capturing the revenue dynamics.

TARS Tarsus Pharma Sales Growth QoQ (07/04/2022 - 11/20/2026)

Tarsus Pharmaceuticals, Inc. (TARS) - metric breakdowns and financial figures

- stock price and consensus target price:
- cash and cash flow metrics:
Analysis of all company metrics:TARS - Tarsus Pharmaceuticals
Flagship merchandise of tarsusrx.com

Investors are assessing the market expansion of Tarsus Pharmaceuticals (TARS) through the efficiency of its commercial division and the research team's ability to scale sales of new drugs. This metric measures the growth rate of operating income between quarters, allowing for the timely identification of revenue stagnation via the relative quarterly change in revenue to confirm the business's long-term capitalization potential.